1. Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

3. TNBC Overview

4. TNBC Subtypes

5. Case Overview

6. Recommended Regimens for the First-Line Treatment of MBC

7. TNT Study: Carboplatin vs Docetaxel in Advanced TNBC or BRCA1/2-Positive MBC

8. tnAcity: Phase 2 Trial of Nab-Paclitaxel and Carboplatin in Front-Line Metastatic TNBC

9. Androgen Signaling and TNBC

10. Targeting the AR Pathway in TNBC Bicalutamide

11. Phase 2 Single-Arm Study of Bicalutamide in AR-Positive, ER-Negative MBC

12. Targeting the AR Pathway in TNBC Enzalutamide

13. Phase 2 Study of Enzalutamide in Advanced AR-Positive TNBC

14. ENDEAR: Phase 3 Trial of Enzalutamide-Positive Paclitaxel in Advanced Diagnostic-Positive TNBC

15. UCBG 12-1: Phase 2 Trial of Abiraterone Acetate-Prednisone in Advanced AR-Positive TNBC

16. Phase 1b/2 Data for Pembrolizumab in Advanced TNBC

17. Ongoing Studies of Immune Checkpoint Inhibitors in Advanced TNBC

18. PARP Inhibitors in TNBC

19. Randomized Phase 2 Trial of Veliparib and Cyclophosphamide in Advanced TNBC

20. Phase 1 Trial of Olaparib and Paclitaxel in TNBC

21. PARP Inhibitors in BRCA-Mutated MBC

22. Phase 2 Study of Lurbinectedin in BRCA-Mutated MBC

23. Antibody-Drug Conjugates in Development for TNBC

24. Concluding Remarks